Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Staci L. Haney1, Michelle L. Varney1, Jacob T. Williams1, Lynette M. Smith2, Geoffrey Talmon3 and Sarah A. Holstein1*

Abstract

Background: Multiple myeloma (MM) remains an incurable malignancy, despite the advent of therapies such as proteosome inhibitors (PIs) that disrupt protein homeostasis and induce ER stress. We have pursued inhibition of geranylgeranyl diphosphate synthase (GGDPS) as a novel mechanism by which to target protein homeostasis in MM cells. GGDPS inhibitors (GGSI) disrupt Rab geranylgeranylation, which in turn results in perturbation of Rab-mediated protein trafficking, leading to accumulation of intracellular monoclonal protein, induction of ER stress and apoptosis. Our lead GGSI, RAM2061, has demonstrated favorable pharmacokinetic properties and in vivo efficacy. Here we sought to evaluate if combination therapy with GGSI and PI would result in enhanced disruption of the unfolded protein response (UPR) and increase anti-MM efficacy.

Methods: MTT assays were conducted to evaluate the cytotoxic effects of combining RAM2061 with bortezomib in human MM cells. The effects of RAM2061 and/or PI (bortezomib or carfilzomib) on markers of UPR and apoptosis were evaluated by a combination of immunoblot (ATF4, IRE1, p-eIF2a, cleaved caspases and PARP), RT-PCR (ATF4, ATF6, CHOP, PERK, IRE1) and flow cytometry (Annexin-V). Induction of immunogenic cell death (ICD) was assessed by immunoblot (HMGB1 release) and flow cytometry (calreticulin translocation). Cell assays were performed using both concurrent and sequential incubation with PIs. To evaluate the in vivo activity of GGSI/PI, a flank xenograft using MM.1S cells was performed.

Results: Isobologram analysis of cytotoxicity data revealed that sequential treatment of bortezomib with RAM2061 has a synergistic effect in MM cells, while concurrent treatment was primarily additive or mildly antagonistic. The effect of PIs on augmenting RAM2061-induced upregulation of UPR and apoptotic markers was dependent on timing of the PI exposure. Combination treatment with RAM2061 and bortezomib enhanced activation of ICD pathway markers. Lastly, combination treatment slowed MM tumor growth and lengthened survival in a MM xenograft model without evidence of off-target toxicity.

Conclusion: We demonstrate that GGSI/PI treatment can potentiate activation of the UPR and apoptotic pathway, as well as induce upregulation of markers associated with the ICD pathway. Collectively, these findings lay the groundwork for future clinical studies evaluating combination GGSI and PI therapy in patients with MM.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
diagnosed in 2021. MM cells produce and secrete large quantities of monoclonal proteins (MP), which can be detected in the peripheral blood. To alleviate endoplasmic reticulum (ER) stress from the continuous manufacturing of MP, MM cells express near maximal levels of unfolded protein response (UPR) associated proteins and therefore are particularly sensitive to activation of the pro-apoptotic arm of the UPR [1, 2]. Disruption of the machinery regulating protein homeostasis and the resulting induction of ER stress-associated apoptosis serves as a targeted therapeutic strategy against MM [3–5]. Current front-line and relapsed/refractory treatments for MM include proteasome inhibitors (PIs), which work by blocking the proteasome from recycling misfolded proteins, leading to ER stress and apoptosis [6–8]. The FDA approved the first-in-class PI, bortezomib, in 2003 followed by the second-generation PI, carfilzomib, in 2012. While PIs have proven very beneficial for the treatment of MM, development of relapsed/refractory MM remains a significant clinical challenge [9–11] and necessitates the need for novel therapies.

As an alternative strategy by which to target protein homeostasis in MM, we have focused on the development of geranylgeranyl diphosphate synthase (GGDPS) inhibitors (GGSIs) [12–21]. In the isoprenoid biosynthetic pathway (IBP), GGDPS catalyzes the synthesis of the isoprenoid donor (GGPP) which in turn is covalently linked to the target Rab proteins by the enzyme geranylgeranyl transferase (GGTase) II. Rabs regulate nearly all intracellular trafficking events and require geranylgeranylation in order to be properly localized and functional [22]. We have shown that agents that impair Rab geranylgeranylation induce MM cell death by disrupting the trafficking of MP, resulting in induction of the UPR and apoptosis [23–25]. We have previously reported preclinical studies with our lead GGSI, RAM2061, which demonstrated the agent’s metabolic stability, prolonged half-life, systemic distribution, in vivo disruption of geranylgeranylation and anti-tumor efficacy in a mouse MM xenograft model [24].

We hypothesized that the combination of GGS1 and PI therapy would result in enhanced activation of the UPR and increase anti-MM efficacy. Here we demonstrate that combination treatment with RAM2061 and PI (bortezomib or carfilzomib) enhances UPR activation and MM cell death in vitro when compared to single drug treatment, and that these effects are dependent on the timing of drug exposure. In addition, combination therapy induces activation of the immunogenic cell death pathway (ICD). Furthermore, combination GGS1 and bortezomib treatment significantly slowed in vivo tumor growth and lengthened survival relative to single drug treatments in a mouse MM xenograft model. Collectively, these studies are the first to demonstrate the feasibility and therapeutic benefit of combining GGS1 and PIs and lay the foundation for future clinical studies.

**Methods**

**Chemicals**

Dr. David Wiemer at the University of Iowa kindly provided RAM2061 [18]. Compound purity was determined as ≥ 95% by high-performance liquid chromatography and verified by nuclear magnetic resonance [18]. Bortezomib was purchased from Millipore sigma (Burlington, MA, USA) and carfilzomib was purchased from Amgen (Thousand Oaks, CA, USA).

**Cell culture**

MM.1S and RPMI-8226 cells were obtained from American Type Culture Collection (Manassas, VA, USA). JJN3 cells were obtained from DSMZ-German Collection of Microorganisms and Cell Cultures. ALMC-2 cells [26] were obtained from Dr. Diane Jelinek, Mayo Clinic (Rochester, MN). Cells were grown in media supplemented with 10% heat-inactivated fetal bovine serum (20% for JJN3), glutamine, and penicillin–streptomycin at 37 °C and 5% CO2. Mycoplasma testing was performed using MycoAlert mycoplasma detection kit (Lonza, Rockland, ME, USA).

**MTT**

Cells were plated (3.5 × 10^4 cells/150 μL per well) in 96-well plates and incubated in the presence or absence of drug. The MTT assay was performed as previously described [27]. Data were normalized so that the absorbance acquired from cells treated with solvent only was defined as having an MTT activity of 100%.

**ELISA**

A human lambda ELISA kit (Bethyl Laboratories, Montgomery, TX, USA) was used to quantify intracellular monoclonal protein levels from the cell culture studies (ALMC-2, RPMI-8226 and MM.1S) as well as the levels of human lambda light chain in the blood samples from the xenograft study. Intracellular kappa light chain levels were detected in JJN3 cells using a human kappa ELISA kit (Bethyl Laboratories).

**Detection of apoptosis by flow cytometry**

Cells were incubated for 48 h in the presence of RAM2061. PI (bortezomib or carfilzomib) was added either concurrently or sequentially (24 h after RAM2061). Cells were washed with PBS and stained with APC-conjugated Annexin V antibody and propidium iodide per the manufacturer’s instruction (eBioscience, San Diego, CA, USA). Ten-thousand cell events were recorded using
a BD LSRII flow cytometer. FlowJo software was used for all data analysis. We define early apoptotic cells as being Annexin V+/Propidium iodide− and late apoptotic as Annexin V+/Propidium iodide+.  

**Detection of cell surface calreticulin**  
Cells were incubated for 48 h in the presence of RAM2061. PI (bortezomib or carfilzomib) was added either concurrently or sequentially (24 h after RAM2061). Cells were washed with PBS and incubated with calreticulin polyclonal antibody (1:200, Invitrogen PA3-900), followed by secondary anti-rabbit Alexafluor594. Ten-thousand cell events were recorded using a BD LSRII flow cytometer. FlowJo software was used for all data analysis.

**Immunoblot**  
Cells were incubated for the specified amount of time in the presence or absence of RAM2061, bortezomib or carfilzomib. Cells were washed with phosphate-buffered saline (PBS) and lysed in RIPA buffer (1% sodium deoxycholate, 0.15 M NaCl, 0.1% SDS, 1% (v/v) Triton X-100, 0.05 M Tris HCl, pH 7.4) supplemented with protease and phosphatase inhibitors. Protein concentration was determined using the BCA method. Protein (15 µg) was run on an SDS-PAGE gel and transferred to a polyvinylidene difluoride membrane. Blots were incubated overnight in primary antibody and for 1 h in secondary antibody. Protein was visualized using a chemiluminescence detection kit and a Bio-Rad Chemidoc MP imaging system. Antibodies used for these assays can be found in the Additional file 1: Table S1.

**Quantitative real-time polymerase chain reaction**  
Cells were incubated for the specified amount of time in the presence or absence of RAM2061, bortezomib or carfilzomib. RNA was isolated using the E.Z.N.A HP total RNA kit from Omega Biotek (Norcross, GA, USA). RNA (1 µg) was reverse-transcribed to cDNA using the i-Script cDNA synthesis kit (Bio-Rad, Hercules, CA) and mixed with gene-specific primers and i-Taq Sybr green super mix (Bio-Rad) according to manufacturer’s instruction. qRT-PCR reactions were performed in triplicate using a Bio-Rad CFX96 instrument. Data analysis was performed using the Bio-Rad CFX manager 3.1 software. Gene expression was normalized to that of β-actin. Primer sequences used in these studies can be found in Additional file 1: Table S2.

**Myeloma xenografts**  
Female NOD/SCID mice (Charles River) between the ages of 6–8 weeks were housed in the University of Nebraska Medical Center (UNMC) animal facility at a temperature of 23–25 °C, relative humidity of 50–70% and 12/12-h light/dark cycles. The UNMC IACUC (protocol number 16-132-11-FC) approved all animal studies. NOD-SCID mice were subcutaneously inoculated in the flank with MM.1S cells (10 million cells in 0.1 mL of sterile saline mixed 1:1 with Matrigel). When tumors became palpable (approximately 2 weeks), mice were divided into control and treatment groups to provide an equal distribution of tumor size for each group at the start of treatment (n = 8). Our pre-established practice is to exclude mice that do not have palpable tumors by the start of treatment. Thus, one mouse from both the control and RAM2061 group were excluded due to lack of tumor engraftment. Controls were administered 100 µL PBS 2×/wk (IV). Bortezomib was administered subcutaneously at a dose of 0.3 mg/kg 2×/wk. RAM2061 was administered IV at a dose of 0.08 mg/kg 2×/wk. All mice began treatment on day 14 post MM cell inoculation. Tumor volume was recorded three times per week using a caliper. Investigators were not blinded during the course of this experiment. The following equation was used to calculate tumor volume: 4π/3 × (width/2)² × (length/2).

**Blood analysis**  
Blood samples were obtained postmortem from the heart and analyzed using an Abaxis Vetscan2 instrument and the preventive profile plus rotor (Allied Analytic, Tampa, FL).

**Histology**  
Mouse organs were fixed in formalin for 24–96 h, stored in 70% ethanol, embedded in paraffin, sectioned, and stained (H&E or with anti-cleaved caspase 3 antibody) using standard methods at the UNMC Tissue Science Facility. To quantify the cleaved caspase 3 data, stained cells from five fields of view/sample were manually counted (ImageJ software) and averages were calculated for each sample.

**Statistics**  
T-tests (two-tailed) were used to calculate statistical significance between control and treated groups. Linear mixed models (LMM) were used to look at changes in tumor burden over time. Tumor burden was modeled on the log10 scale in order to meet model assumptions. The model included fixed effects for group, day and the group x day interaction and day is modeled as a continuous variable. A random slope and intercept were fit for each mouse. Distributional assumptions of the LMM were assessed using residual plots and the linearity and equal variance assumptions were found to be met when data was analyzed on the log10 scale. Kaplan–Meier
synergistic interaction (CI < 1) while concurrent treatment was primarily additive (CI = 1) to antagonistic (CI > 1) (Additional file 1: Fig. S1). Additional MTT assays were performed using the PI carfilzomib. We also observed primary synergistic (CI < 1) to additive (CI = 1) interactions following sequential treatment of carfilzomib with RAM2061, and a primarily additive (CI = 1) to antagonistic (CI > 1) interaction when using concurrent carfilzomib and RAM2061 (Additional file 1: Fig. S2, Table S3).

To explore further the impact of timing of PI administration on induction of cell death with RAM2061, we assessed induction of apoptosis by flow cytometry using Annexin V and propidium iodide staining. Relative to single treatment controls, both concurrent and sequential treatment of bortezomib with RAM2061 lead to an increase in the percent of apoptotic cells (Fig. 1). Conversely, we did not observe a similar increase in apoptotic cells in cell lines treated with RAM2061 in combination with another PI, carfilzomib (Additional file 1: Fig. S3). We also examined induction of apoptosis via immunoblot analysis of cleaved PARP, caspases 3, 8, and 9. MM cells were incubated in the presence or absence of RAM2061 (50 or 100 nM) for 48 h. PI was added concurrent with RAM2061 or either 6 h (denoted as **) or 24 h (denoted as *) prior to cell harvest. We observed increased PARP and caspase cleavage in MM cells treated with RAM2061 and 6-h sequential treatment of either bortezomib or carfilzomib when compared to single drug treatment (Fig. 2a). Likewise, MM cells treated with RAM2061 and 24-h sequential bortezomib or carfilzomib displayed enhanced apoptotic markers relative to single treatment controls (Fig. 2b). Conversely, concurrent treatment with PI resulted in more rapid cell death and a consequent decrease in protein levels was observed (Additional file 1: Fig. S4).

### Comparison of UPR induction with concurrent vs sequential PI therapy in combination with RAM2061

Next, we examined markers of the UPR (ATF4, IRE1 and phosphorylated-elf2α (p-elf2 α)) using the same sequential and concurrent PI treatment as previously described. These studies revealed that administration of either bortezomib or carfilzomib during the final 6 h or final 24 h of incubation enhanced the RAM2061-induced upregulation of UPR markers in a cell line-specific manner (Fig. 3a and b). Concurrent 48-h treatment with PI led to rapid apoptosis and a subsequent decrease in UPR markers, likely due to the rapid effects of PI on the UPR pathway (Additional file 1: Fig. S5). qRT-PCR analysis of UPR markers revealed a partial and cell line-dependent increase in ATF4, AT6, CHOP, IRE1 and PERK expression levels following 6- and 24-h incubation of PI with
RAM2061 relative to single treatment controls (Additional file 1: Fig. S6 and S7). Neither bortezomib nor carfilzomib enhanced RAM2061-mediated intracellular light chain retention as measured by ELISA (Additional file 1: Fig. S8).

Combination treatment with RAM2061 and PI leads to induction of the ICD pathway

Next, we sought to determine if GGSI treatment, either alone or in combination with a PI, could induce the immunogenic cell death (ICD) pathway. This pathway is characterized by cell-surface translocation of calreticulin, release of damage-associated molecular pattern (DAMP) molecules (including HMGB1 (high mobility group protein B1)) and stimulation of type I interferon (IFN) responses. To measure HMBGI release, we performed immunoblot analysis on media collected from MM cells incubated with RAM2061 and PI. Both 24- and 48-h PI treatment in the presence of RAM2061 enhanced the release of HMGB1 into the media (Fig. 4a). Bortezomib induced cell-surface translocation of calreticulin following both 24- and 48-h incubation in all four cell lines, while carfilzomib and RAM2061 had little effect on cell surface levels of calreticulin when used as single agents (Fig. 4b, c and Additional file 1: Fig. S9). Both concurrent and sequential incubation of bortezomib in the presence of RAM2061 enhanced cell surface translocation of calreticulin relative to single drug treatments (Fig. 4b, c).
Using a MM flank xenograft model, we examined if combination treatment of bortezomib with RAM2061 would be efficacious in slowing tumor growth in vivo. NOD-SCID mice were inoculated with MM.1S cells in the flank and treated with PBS (control), bortezomib, RAM2061, or a combination of RAM2061/bortezomib. Tumor growth over time was significantly decreased in the RAM2061 (p = 0.0009) and in the RAM2061/bortezomib (p = 0.0002) treatment groups compared to control animals (Fig. 5a). In addition, survival, or time to sacrifice, was significantly prolonged in the RAM2061/bortezomib cohort (p = 0.003), but not the RAM2061 group (p = 0.09, Fig. 5b). Concordant with tumor volume, mean plasma human lambda light chain levels were decreased in the RAM2061 and to a larger degree in the RAM2061/bortezomib treatment groups when compared to the control mice (p < 0.05, Fig. 5c). Consistent with our previous in vivo studies, the primary toxicity associated with RAM2061 treatment was hepatic transaminase elevation (Additional file 1: Table S4). Histological examination of livers revealed mild and variable lobular unrest (defined as variable nuclear enlargement with a rare binucleated hepatocyte) around the central vein (zone 3) likely related to mild regenerative changes in bortezomib treated mice (Additional file 1: Fig. S10). Livers of RAM2061-treated mice displayed prominent lobular unrest around zone 3 with rare apoptotic hepatocytes and occasional lipofuscin-laden macrophages which signify hepatocyte dropout. Livers of mice treated with both drugs showed the same prominent lobular in zone 3 with adjacent ballooning degeneration in zone 2 hepatocytes. Spleen and kidney morphology were normal across all groups (Additional file 1: Fig. S10). No additional toxicity was observed when bortezomib was combined with RAM2061 based on animal weight, renal or hepatic parameters (Additional file 1: Fig. S11 and Table S4). We observed a trend toward greater cleaved caspase 3 expression in tumors isolated from mice treated with RAM2061 relative to controls (Additional file 1: Fig. S12).
Discussion

RAM2061 is a homoneryl triazole bisphosphate that functions as a potent GGDPs inhibitor with an IC\textsubscript{50} of 86 nM and lowest effective concentration in MM cells of 25 nM [18]. Our preclinical studies demonstrate that RAM2061 displays a prolonged terminal half-life of 29.2 h, metabolic stability, in vivo target effects, and systemic distribution including favorable bone marrow exposure [24]. In addition, single agent activity was observed in a xenograft model using human MM.1S cells. Notably, this is the first study to show that RAM2061 and bortezomib have synergistic cytotoxic activity in MM cells. Further investigation revealed that bortezomib and carfilzomib are able to potentiate induction of markers of the UPR and ICD pathways in the presence of RAM2061. In addition, we present the first in vivo investigation showing the anti-tumor effects of combination GGSI/PI inhibitor therapy in a xenograft tumor model.

The proteasome is tasked with degrading the majority of cellular proteins and thus plays a pivotal role in maintaining protein homeostasis. PIs induce MM cell death via various well-documented mechanisms, including the inhibition of several pro-survival factors, such as cytokines, adhesion molecules, angiogenesis, and NF-κB [6–8, 28]. In addition, PI-mediated accumulation of misfolded protein and induction of the UPR in MM cells has been described by several accounts in the literature. One study showed that bortezomib induced the accumulation of misfolded ER-processed proteins, which led to activation of the pro-apoptotic arm of the UPR, and that MM cells sensitivity to bortezomib directly correlates with the amount of MP retained in the cell [1]. In another study, a specific inhibitor of the proteasome β2 subunit activated the UPR and induced cytotoxicity in bortezomib-resistant MM cells when combined with either bortezomib or carfilzomib [29]. Dual inhibition of the β2 and β5 subunits using a PI termed syringolog-1 resulted in increased expression of CHOP, ATF3, and XBP1, as well as induction of apoptosis in both bortezomib resistant and sensitive cell lines [30]. Likewise, we observed upregulation of several UPR mediators upon bortezomib or carfilzomib treatment, including ATF4, p-eIF2a, and eIF2α was performed. β-tubulin is shown as a loading control. Blots are representative of three independent experiments.

Fig. 3 Effects of sequential PI therapy in combination with RAM2061 on markers of the unfolded protein response. MM cells were incubated with RAM2061 (50 or 100 nM) for 48 h with or without sequential PI treatment. Bortezomib or carfilzomib was added either a 6 h (denoted by **) or b 24 h (denoted by *) prior to cell harvest (Bor: 3 nM (MM.1S), 5 nM (JJN3 and RPMI-8226), 15 nM (ALMC-2), Carf: 20 nM). Immunoblot analysis for ATF4, IRE1, p-eIF2a, and eIF2a was performed. β-tubulin is shown as a loading control. Blots are representative of three independent experiments.
Fig. 4 Combination treatment with RAM2061 and PI leads to induction of the ICD pathway markers. MM cells were incubated with RAM2061 (50 or 100 nM) for 48 h with or without sequential (added after 24 h, denoted by *) or concurrent PI treatment (Bor: 3 nM (MM.1S), 5 nM (JJN3 and RPMI-8226), 15 nM (ALMC-2), Carf: 20 nM). a Immunoblot analysis of secreted HMGB1 was performed using media collected from cells. b, c Cell surface levels of calreticulin were measured by flow cytometry. Data are expressed as the average percentage of calreticulin positive (n = 3, data are displayed as mean ± stdev, * denotes p < 0.05, ** denotes p < 0.01, *** denotes p < 0.001 per t-test). Blots are representative of three independent experiments.
IRE1, and p-eIF2a. Our current and previous studies have demonstrated that GGSIs induce all three arms of the UPR [23–25]. While our current studies showed several UPR markers that were further upregulated following combination therapy, the underlying mechanism does not appear to be a direct consequence of accumulation of intracellular MP as the addition of PI did not enhance the effects of the GGSI (Additional file 1: Fig. S8). Prior work has demonstrated that PIs can induce utilization of non-proteasome-mediated degradation pathways such as aggresomes and autophagosomes, thus alleviating the ER stress [31–34]. However, our prior studies with IBP inhibitors demonstrated that these agents do not increase aggresome numbers in MM cells and that the accumulated intracellular MP induced by these inhibitors is not a substrate for aggresomes, autophagosomes or lysosomes [35]. Notably, the effect of PIs on augmenting RAM2061-induced upregulation of UPR markers was both concentration- and time-dependent. Concurrent exposure results in less induction of the UPR pathway, likely as a result of the more rapid effects of bortezomib on this pathway relative to RAM2061, with subsequent decrease in markers as cells undergo apoptosis. These results likely contribute to the effects observed in the MTT assays, where concurrent treatment appeared to induce less robust effects on cytotoxicity (as indicated by CI's showing additive/antagonistic interactions) than sequential treatment strategies. Further studies are needed to dissect the mechanisms underlying the interactions between the two classes of drugs on the UPR and apoptotic pathways and to explore alternative dosing schedules that would maximize in vivo efficacy.

There is rationale in the literature to suggest that use of IBP pathway inhibitors would be of therapeutic value as anti-cancer agents. Two studies using the GGDPS inhibitor GGOHBP showed in vivo reduction in tumor burden...
in both adrenal and prostate cancer xenografts [36, 37]. Another preclinical study using a series of thienopyrimidine-based GGDS inhibitors and the a Vκ*MYC transgenic mouse model demonstrated that GGDS inhibition decreased serum MP levels [38]. Our own studies with RAM2061 or a similar structural analog (VSW1198), show single agent activity in both MM.1S flank xenografts as well as pancreatic cancer xenografts [24, 39]. To date, there is one account in the literature that evaluates the benefit of combining IBP pathway inhibitors with PI therapy. This study shows that statins, which inhibit HMG-CoA reductase in the mevalonate pathway and lead to downstream disruption in isoprenoid synthesis, enhanced induction of apoptosis and UPR markers when used in combination with bortezomib in t(4;14)-positive MM cells [40]. Furthermore, using add-back studies they demonstrate that GGPP depletion drives apoptosis and UPR activation in their model. Our present studies have demonstrated synergy between the GGSI and bortezomib in t(4;14)-negative MM cell lines that have other high-risk cytogenetic abnormalities including t(14;16) or del(17p) [26, 41].

While PIs remain the backbone of MM treatment, development of relapsed/refractory disease has led many researchers to begin testing combination PI treatment with inhibitors of lesser explored pathways. Okabe et al. showed that combined treatment with carfilzomib and CUDC-907, a dual PI3-K and histone deacetylase inhibitor, enhanced cellular toxicity in human MM cell lines when compared to single-drug treatment [42]. In another report, inhibition of phosphoglycerate dehydrogenase (PHGDH) using the inhibitor NT-503, significantly potentiated the cytotoxic effect of bortezomib in seven out of eight tested MM cell lines [43]. Furthermore, combination treatment with NCT-503 and bortezomib displayed enhanced anti-tumor effects in the 5T33MM mouse model when compared to single drug treatments. Together, these studies along with our own demonstrate the therapeutic potential of targeting novel pathways in conjunction with the mainstay PIs and may one day lead to the development of new treatment combinations.

Here we demonstrate that in addition to UPR activation, combination GGSI and PI enhanced the activation of the ICD pathway. While it has been overlooked in favor of studying direct cytotoxic effects, understanding and harnessing ICD is now considered equally important in evaluating a drugs mechanism of action [44, 45]. The ICD pathway involves the release of damage-associated molecular patterns (DAMPs) by the cancer cell, which attract and activate antigen-presenting cells leading to antitumor immunity [46]. In culture, bortezomib has been shown to be capable of inducing ICD and antitumor immunity by initiating the uptake of Hsp90-expressing human MM cells by dendritic cells [47]. In our studies, bortezomib was the most potent inducer of ICD markers (calreticulin and HMGB1) as a single agent. There are no accounts in the literature describing either carfilzomib or GGSI effects in inducing ICD, however we demonstrate that both compounds can induce HMGB1 release and calreticulin translocation in a cell-line dependent manner. Future experiments dissecting the role ICD induction by PI/GGSI combination therapies plays in vivo are needed.

Conclusion
In conclusion, our cell culture studies reveal that combination treatment with GGSI and PIs (bortezomib or carfilzomib) increases MM cell death and UPR activation and that this effect is dependent on the timing of drug exposure. Furthermore, we demonstrate that PI/GGSI treatment can potentiate upregulation of markers associated with the immunogenic cell death pathway. These studies are the first to demonstrate the feasibility of combining GGSI and PI therapy in vivo and show evidence of increased efficacy, paving the way towards future preclinical and clinical studies evaluating this novel strategy of disrupting protein homeostasis via multiple mechanisms in MM.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40164-022-00261-6.

Additional file 1. Additional figures and Tables.

Acknowledgements
Not applicable.

Authors’ contributions
SLH and SAH were responsible for the conception and design of the study, as well as writing the manuscript. MLV, JTW and SAH all performed experiments and analyzed data. LMS conducted statistical analysis. GT performed pathology review. All authors read and approved the final manuscript.

Funding
This work was supported by the National Institutes of Health (Grants P30 CA036727 and 1R01CA258621), the American Society of Hematology and the State of Nebraska Department of Health and Human Services (2020-23).

Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its Additional files). The datasets analyzed during this study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.
Competing interests
SAH has received honoraria from BMS/Celgene, Genentech, GSK, Janssen, Oncopeptides, Secura Bio, Takeda. The authors declare that they have no competing interests.

Author details
1 Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. 2 Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA. 3 Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.

Received: 12 November 2021   Accepted: 25 January 2022
Published online: 09 February 2022

References
1. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–16.
2. Ullery A, Lipchick B, Lee KP, Nikiforov MA. Targeting multiple myeloma through the biology of long-lived plasma cells. Cancers. 2020;12:2117.
3. Cenci S, Sitia R. Managing and exploiting stress in the factory. FEBS Lett. 2007;581:3622–7.
4. Kubick T, Gil L, Dytfeld D. Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement. Pol Arch Intern Med. 2021;131:361–8.
5. Wrath M, Schick M, Keller U, Kronek J. Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy. Cancers. 2020;12:3764.
6. Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol. 2016;104:273–80.
7. Guerrero-Garcia TA, Gandolf S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, et al. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018;15:1033–52.
8. Gandolf S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561–84.
9. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahls N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105–15.
10. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.
11. Dhanaes S, Holler-Hann G, Stothard C, Dhande DS, Davies FE, Rodriguez-Otero P. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMEN Study. Clin Ther. 2021;43:1983–96.
12. Haney SL, Willis VS, Wiemer DF, Holstein SA. Recent advances in the development of mammalian geranylgeranyl diphosphate synthase inhibitors. Molecules. 2017;22:886.
13. Zhou X, Fenner SD, Willis VS, Born EJ, Tong H, Wiemer DF, et al. Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorg Med Chem. 2014;22:2791–8.
14. Willis VS, Allen C, Holstein SA, Wiemer DF. Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase. ACS Med Chem Lett. 2015;6:1195–8.
15. Foust BJ, Allen C, Holstein SA, Wiemer DF. A new motif for inhibitors of geranylgeranyl diphosphate synthase. Bioorg Med Chem. 2016;24:3734–41.
16. Allen C, Cortagere S, Tong H, Matthiesen RA, Metzger JI, Wiemer DF, et al. Olefin isomers of a triazole bisphosphonate synergistically inhibit geranylgeranyl diphosphate synthase. Mol Pharmacol. 2017;91:229–36.
17. Willis VS, Metzger JI, Allen C, Varney ML, Wiemer DF, Holstein SA. Bisnorisooprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorg Med Chem. 2017;25:2437–44.
18. Matthiesen RA, Varney ML, Xu PC, Rier AS, Wiemer DF, Holstein SA. alpha-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2018;26:376–85.
19. Bhujian NH, Varney ML, Bhattacharya DS, Payne WM, Mohs AV, Holstein SA et al. omega-Hydroxy isoprenoid bisphosphonates as linkable GOPPS inhibitors. Bioorg Med Chem Lett. 2019;29:126633.
20. Goetz DB, Varney ML, Wiemer DF, Holstein SA. Amides as biososteres of triazole-based geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2020;28:115604.
21. Fairweather AER, Goetz DB, Schroeder CM, Bhujian NH, Varney ML, Wiemer DF, et al. Impact of alpha-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2021;44:116307.
22. Gomes AQ, Ali BR, Ramalho JS, Godfrey RF, Barral DC, Hume AN, et al. Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell. 2003;14:1882–99.
23. Holstein SA, Hohi RJ. Isooprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leuk Res. 2011;35:551–9.
24. Haney SL, Chhonker YS, Varney ML, Talmon G, Smith LM, Murry DJ, et al. In vivo evaluation of isoprenoid triazole bisphosphonate inhibitors of geranylgeranyl diphosphate synthase: impact of olefin stereochemistry on toxicity and biodistribution. J Pharmacol Exp Ther. 2019;371:327–38.
25. Born EJ, Hartman SV, Holstein SA. Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells. Blood Cancer J. 2013;3:167.
26. Arendt BK, Ramirez-Alvarado M, Sikkinink LA, Keats JJ, Ahmann GJ, Dispenzieri A, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secretary human cell lines, ALMC-1 and ALMC-2. Blood. 2008;112:1931–41.
27. Holstein SA, Hohi RJ. Interaction of cytosome arabinoside and lovastain in human leukemia cells. Leuk Res. 2001;25:651–60.
28. Okazuka K, Ishida T. Proteasome inhibitors in multiple myeloma. Jpn J Clin Oncol. 2018;48:785–93.
29. Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Sizle T, et al. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica. 2015;100:1350–60.
30. Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, et al. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome and proteasome targeting β2 and β5 subunits. Oncotarget. 2018;9:9975–91.
31. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009;8:1974–84.
32. Riz I, Hawley TS, Hawley RG. KL4-FSQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget. 2015;6:14814–31.
33. Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abdi El-Azeem HG, et al. Molecular chaperone GRP78 enhances aggressome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget. 2015;6:3098–110.
34. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102:8657–62.
35. Dykstra KM, Allen C, Born EJ, Tong H, Holstein SA. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Oncotarget. 2015;6:41535–49.
36. Reilly JE, Neighbors JD, Hohi RJ. Targeting proteasome geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biol Ther. 2017;18:872–82.
37. Reilly JE, Neighbors JD, Tong H, Henry MD, Hohi RJ. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis. 2015;32:555–66.
38. Lacbay CM, Waller DD, Park J, Gomez Palou M, Vincent F, Huang XF, et al. Unraveling the prenylation-cancer paradox in multiple myeloma with novel geranylgeranyl pyrophosphate synthase (GOPPS) inhibitors. J Med Chem. 2018;61:6904–17.
39. Haney SL, Varney ML, Chhonker Y, Talmon G, Smith LM, Murry DJ, et al. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway. Pharmacol Res. 2021;167:105528.

40. Longo J, Smimov P, Li Z, Branchard E, van Leeuwen JE, Licht JD, et al. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia. 2021;35:796–808.

41. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31:271–82.

42. Okabe S, Tanaka Y, Gotoh A. Targeting phosphoinositol 3-kinases and histone deacetylases in multiple myeloma. Exp Hematol Oncol. 2021;10:19.

43. Elsaadi S, Steiro I, Abdollahi P, Vandsemb EN, Yang R, Slordahl TS, et al. Targeting phosphoglycerate dehydrogenase in multiple myeloma. Exp Hematol Oncol. 2021;10:3.

44. Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol. 2019;7:50.

45. Fabian KP, Wolfson B, Hodge JW. From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment. Front Oncol. 2021;11:728018.

46. Wang Y, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5:194–203.

47. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109:4839–45.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.